Breaking News, Promotions & Moves

Nucleus RadioPharma Appoints Dr. Stephen Hahn as CEO

Hahn joins Nucleus RadioPharma after serving as CEO-partner of Flagship Pioneering and CEO of Harbinger Health since 2021.

Nucleus RadioPharma, a contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, has appointed Dr. Stephen M. Hahn as Chief Executive Officer (CEO).

“Steve’s experience as both a physician treating patients and as a leader at the FDA brings an unparalleled perspective to Nucleus as the company works to build the infrastructure needed to accelerate the widespread availability of radiopharmaceuticals,” said Justin Butler, partner at Eclipse and Nucleus board member. “His new role is a major indicator to the oncology community that radiopharmaceuticals are the future of precision cancer treatment, and that Nucleus is poised to lead the next era.”

Experience

Hahn joins Nucleus RadioPharma after serving as CEO-partner of Flagship Pioneering and CEO of Harbinger Health since 2021. He served as the 24th U.S. Food and Drug Administration (FDA) commissioner from 2019 to 2021, overseeing both COVID and non-COVID regulatory affairs. Before joining the FDA, he was the chief medical executive at MD Anderson Cancer Center in Houston. The combination of regulatory, clinical and operational knowledge gives him deep insight into how therapies move from clinic to patient.

In his first year as CEO, Hahn will focus on completing the company’s GMP readiness at its Rochester, Minnesota, facility, expanding R&D capabilities, launching Nucleus’ data platform and forging strategic partnerships. Over the next five years, the company aims to dramatically increase manufacturing capacity and advance initiatives that improve patient access worldwide.

“Radiopharmaceuticals are the next frontier of precision oncology care,” said Hahn. “But without the infrastructure to deliver these treatments, their impact is fundamentally limited. At Nucleus RadioPharma, we have an extraordinary team that is committed to breaking those barriers. Together, we will scale the systems and infrastructure needed to make these lifesaving therapies available to all who need them.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters